-
Je něco špatně v tomto záznamu ?
The safety and efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 1b infection
S. Zeuzem, L. Serfaty, J. Vierling, W. Cheng, J. George, J. Sperl, S. Strasser, H. Kumada, P. Hwang, M. Robertson, J. Wahl, E. Barr, R. Talwani, H. Platt,
Jazyk angličtina Země Japonsko
Typ dokumentu časopisecké články
NLK
ProQuest Central
od 1997-03-01 do Před 1 rokem
Medline Complete (EBSCOhost)
od 1998-02-01 do Před 1 rokem
Nursing & Allied Health Database (ProQuest)
od 1997-03-01 do Před 1 rokem
Health & Medicine (ProQuest)
od 1997-03-01 do Před 1 rokem
Family Health Database (ProQuest)
od 1997-03-01 do Před 1 rokem
- MeSH
- antivirové látky škodlivé účinky terapeutické užití MeSH
- benzofurany škodlivé účinky terapeutické užití MeSH
- chinoxaliny škodlivé účinky terapeutické užití MeSH
- chronická hepatitida C komplikace farmakoterapie virologie MeSH
- dospělí MeSH
- genotyp MeSH
- Hepacivirus genetika MeSH
- HIV infekce komplikace MeSH
- imidazoly škodlivé účinky terapeutické užití MeSH
- jaterní cirhóza patofyziologie virologie MeSH
- klinické zkoušky, fáze II jako téma MeSH
- klinické zkoušky, fáze III jako téma MeSH
- koinfekce komplikace MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladiství MeSH
- mladý dospělý MeSH
- retrospektivní studie MeSH
- senioři MeSH
- setrvalá virologická odpověď MeSH
- virová léková rezistence genetika MeSH
- virová nálož MeSH
- virové nestrukturální proteiny genetika MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladiství MeSH
- mladý dospělý MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
BACKGROUND: Genotype 1b (GT1b) is the most common subtype of the hepatitis C virus (HCV). We present an integrated analysis of 1070 participants with HCV GT1b infection from 30 countries who received elbasvir/grazoprevir for 12 weeks. METHODS: This is a retrospective analysis of data from participants with chronic HCV GT1b infection enrolled in 11 phase II/III clinical trials. All participants received elbasvir 50 mg plus grazoprevir 100 mg once daily for 12 weeks. The primary end point of all studies was sustained virologic response 12 weeks after completion of therapy (SVR12, HCV RNA < 15 IU/ml). RESULTS: SVR12 was 97.2% (1040/1070). Of the 30 participants who failed to attain SVR12, 15 relapsed and 15 had nonvirologic failure. Among participant subgroups, SVR12 was high in those with compensated cirrhosis (188/189, 99.5%), HIV co-infection (51/54, 94.4%), and baseline viral load > 800,000 IU/ml (705/728, 96.8%). Resistance-associated substitutions (RASs) at NS5A positions 28, 30, 31, or 93 were present in 21.6% of participants at baseline. SVR12 was 99.6% (820/823) in participants without baseline NS5A RASs and 94.7% (215/227) in those with baseline NS5A RASs. Serious adverse events occurred in 3.2% (34/1070) of participants, nine of which occurred after study medication was completed. CONCLUSIONS: Elbasvir/grazoprevir for 12 weeks represents an effective treatment option for participants with HCV GT1b infection. SVR12 was high in all participant subgroups, including those with compensated cirrhosis, HIV co-infection, and high baseline viral load. CLINICALTRIALS. GOV IDENTIFIERS: The trials discussed in this paper were registered with Clinicaltrial.gov as the following: NCT02092350 (C-SURFER), NCT02105662 (C-EDGE Co-Infection), NCT02105467 (C-EDGE treatment-naive), NCT02105701 (C-EDGE treatment-experienced), NCT01717326 (C-WORTHy), NCT02251990 (C-CORAL), NCT02105688 (C-EDGE COSTAR), NCT02252016 (C-EDGE IBLD), NCT02115321 (C-SALT), NCT02203149 (Japan phase 2/3 study), NCT02358044 (C-EDGE Head-2-Head).
AW Morrow Gastroenterology and Liver Centre Royal Prince Alfred Hospital Sydney NSW Australia
Baylor College of Medicine Advanced Liver Therapies Houston TX USA
Department of Gastroenterology and Hepatology Royal Perth Hospital Perth WA Australia
Department of Hepatology Toranomon Hospital Tokyo Japan
Goethe University Hospital Theodor Stern Kai 7 60590 Frankfurt Germany
Institute for Clinical and Experimental Medicine Prague Czech Republic
Merck and Co Inc Kenilworth NJ USA
Service d'Hépatologie Hôpital Saint Antoine Université Pierre and Marie Curie Paris France
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19028612
- 003
- CZ-PrNML
- 005
- 20200330160246.0
- 007
- ta
- 008
- 190813s2018 ja f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s00535-018-1429-3 $2 doi
- 035 __
- $a (PubMed)29344726
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ja
- 100 1_
- $a Zeuzem, Stefan $u Goethe University Hospital, Theodor-Stern-Kai 7, 60590, Frankfurt, Germany. zeuzem@em.uni-frankfurt.de.
- 245 14
- $a The safety and efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 1b infection / $c S. Zeuzem, L. Serfaty, J. Vierling, W. Cheng, J. George, J. Sperl, S. Strasser, H. Kumada, P. Hwang, M. Robertson, J. Wahl, E. Barr, R. Talwani, H. Platt,
- 520 9_
- $a BACKGROUND: Genotype 1b (GT1b) is the most common subtype of the hepatitis C virus (HCV). We present an integrated analysis of 1070 participants with HCV GT1b infection from 30 countries who received elbasvir/grazoprevir for 12 weeks. METHODS: This is a retrospective analysis of data from participants with chronic HCV GT1b infection enrolled in 11 phase II/III clinical trials. All participants received elbasvir 50 mg plus grazoprevir 100 mg once daily for 12 weeks. The primary end point of all studies was sustained virologic response 12 weeks after completion of therapy (SVR12, HCV RNA < 15 IU/ml). RESULTS: SVR12 was 97.2% (1040/1070). Of the 30 participants who failed to attain SVR12, 15 relapsed and 15 had nonvirologic failure. Among participant subgroups, SVR12 was high in those with compensated cirrhosis (188/189, 99.5%), HIV co-infection (51/54, 94.4%), and baseline viral load > 800,000 IU/ml (705/728, 96.8%). Resistance-associated substitutions (RASs) at NS5A positions 28, 30, 31, or 93 were present in 21.6% of participants at baseline. SVR12 was 99.6% (820/823) in participants without baseline NS5A RASs and 94.7% (215/227) in those with baseline NS5A RASs. Serious adverse events occurred in 3.2% (34/1070) of participants, nine of which occurred after study medication was completed. CONCLUSIONS: Elbasvir/grazoprevir for 12 weeks represents an effective treatment option for participants with HCV GT1b infection. SVR12 was high in all participant subgroups, including those with compensated cirrhosis, HIV co-infection, and high baseline viral load. CLINICALTRIALS. GOV IDENTIFIERS: The trials discussed in this paper were registered with Clinicaltrial.gov as the following: NCT02092350 (C-SURFER), NCT02105662 (C-EDGE Co-Infection), NCT02105467 (C-EDGE treatment-naive), NCT02105701 (C-EDGE treatment-experienced), NCT01717326 (C-WORTHy), NCT02251990 (C-CORAL), NCT02105688 (C-EDGE COSTAR), NCT02252016 (C-EDGE IBLD), NCT02115321 (C-SALT), NCT02203149 (Japan phase 2/3 study), NCT02358044 (C-EDGE Head-2-Head).
- 650 _2
- $a mladiství $7 D000293
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a antivirové látky $x škodlivé účinky $x terapeutické užití $7 D000998
- 650 _2
- $a benzofurany $x škodlivé účinky $x terapeutické užití $7 D001572
- 650 _2
- $a klinické zkoušky, fáze II jako téma $7 D017322
- 650 _2
- $a klinické zkoušky, fáze III jako téma $7 D017326
- 650 _2
- $a koinfekce $x komplikace $7 D060085
- 650 _2
- $a virová léková rezistence $x genetika $7 D024882
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a genotyp $7 D005838
- 650 _2
- $a HIV infekce $x komplikace $7 D015658
- 650 _2
- $a Hepacivirus $x genetika $7 D016174
- 650 _2
- $a chronická hepatitida C $x komplikace $x farmakoterapie $x virologie $7 D019698
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a imidazoly $x škodlivé účinky $x terapeutické užití $7 D007093
- 650 _2
- $a jaterní cirhóza $x patofyziologie $x virologie $7 D008103
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a chinoxaliny $x škodlivé účinky $x terapeutické užití $7 D011810
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 _2
- $a setrvalá virologická odpověď $7 D000072230
- 650 _2
- $a virová nálož $7 D019562
- 650 _2
- $a virové nestrukturální proteiny $x genetika $7 D017361
- 650 _2
- $a mladý dospělý $7 D055815
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Serfaty, Lawrence $u Service d'Hépatologie, Hôpital Saint-Antoine, Université Pierre and Marie Curie, Paris, France.
- 700 1_
- $a Vierling, John M. $7 xx0246231 $u Baylor College of Medicine, Advanced Liver Therapies, Houston, TX, USA.
- 700 1_
- $a Cheng, Wendy $u Department of Gastroenterology and Hepatology, Royal Perth Hospital, Perth, WA, Australia.
- 700 1_
- $a George, Jacob $u Storr Liver Centre, Westmead Institute for Medical Research, Westmead Hospital and University of Sydney, Sydney, NSW, Australia.
- 700 1_
- $a Sperl, Jan $u Institute for Clinical and Experimental Medicine (IKEM), Prague, Czech Republic.
- 700 1_
- $a Strasser, Simone $u AW Morrow Gastroenterology and Liver Centre, Royal Prince Alfred Hospital, Sydney, NSW, Australia.
- 700 1_
- $a Kumada, Hiromitsu $u Department of Hepatology, Toranomon Hospital, Tokyo, Japan.
- 700 1_
- $a Hwang, Peggy $u Merck & Co., Inc., Kenilworth, NJ, USA.
- 700 1_
- $a Robertson, Michael $u Merck & Co., Inc., Kenilworth, NJ, USA.
- 700 1_
- $a Wahl, Janice $u Merck & Co., Inc., Kenilworth, NJ, USA.
- 700 1_
- $a Barr, Eliav $u Merck & Co., Inc., Kenilworth, NJ, USA.
- 700 1_
- $a Talwani, Rohit $u Merck & Co., Inc., Kenilworth, NJ, USA.
- 700 1_
- $a Platt, Heather $u Merck & Co., Inc., Kenilworth, NJ, USA.
- 773 0_
- $w MED00002687 $t Journal of gastroenterology $x 1435-5922 $g Roč. 53, č. 5 (2018), s. 679-688
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/29344726 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20190813 $b ABA008
- 991 __
- $a 20200330160717 $b ABA008
- 999 __
- $a ok $b bmc $g 1433761 $s 1067072
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2018 $b 53 $c 5 $d 679-688 $e 20180117 $i 1435-5922 $m Journal of gastroenterology $n J Gastroenterol $x MED00002687
- LZP __
- $a Pubmed-20190813